UBS Group’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

UBS Group’s Portfolio RPTP Stock Details RPTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,100	Closed	-$19K	–	8528
2016 Q3	$19K	Sell	2,100 -110,918	-98%	-$789K	﹤0.01%	6368
2016 Q2	$607K	Sell	113,018 -25,341	-18%	-$130K	﹤0.01%	3757
2016 Q1	$636K	Sell	138,359 -7,881	-5%	-$31.7K	﹤0.01%	3596
2015 Q4	$760K	Buy	146,240 +98,411	+206%	+$571K	﹤0.01%	3626
2015 Q3	$289K	Buy	47,829 +44,461	+1,320%	+$545K	﹤0.01%	4348
2015 Q2	$53K	Buy	3,368 +468	+16%	+$5.68K	﹤0.01%	5978
2015 Q1	$31K	Sell	2,900 -1,535	-35%	-$15.7K	﹤0.01%	6532
2014 Q4	$47K	Buy	+4,435	New	+$43.3K	﹤0.01%	6580

UBS Group's RPTP Position: Q4 2016 in Review

UBS Group sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 2,100 shares — an estimated $19K sold.

UBS Group first reported a position in RPTP in Q4 2014 and held it in 8 quarters. The position peaked at $760K in Q4 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

UBS Group reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
UBS Group sold 2,100 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $19K.
UBS Group first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q4 2014 and held it in 8 quarters.
UBS Group's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $760K in Q4 2015.
0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.